A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer

Trial Profile

A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Paricalcitol (Primary) ; Pembrolizumab (Primary) ; Gemcitabine; Paclitaxel
  • Indications Carcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Feb 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Feb 2020.
    • 21 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 08 Dec 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top